{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mouth+Disease&page=18",
    "query": {
      "condition": "Mouth Disease",
      "page": 18
    },
    "page_size": 10
  },
  "pagination": {
    "page": 18,
    "page_size": 10,
    "total_count": 5918,
    "total_pages": 592,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mouth+Disease&page=19&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Mouth+Disease&page=17&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T15:58:17.938Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00161694",
      "title": "Use of Sucrose to Relieve Pain During Eye Exams in Infants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Apnea of Prematurity",
        "Retinopathy of Prematurity",
        "Pain"
      ],
      "interventions": [
        {
          "name": "sucrose solution",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Weeks",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "5 Weeks and older"
      },
      "enrollment_count": 300,
      "start_date": "2005-07",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-06-04",
      "last_synced_at": "2026-10-24T15:58:17.938Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00161694"
    },
    {
      "nct_id": "NCT04060173",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ABP-671",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperuricemia",
        "Gout"
      ],
      "interventions": [
        {
          "name": "ABP-671",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Atom Therapeutics Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 27,
      "start_date": "2019-09-05",
      "completion_date": "2020-02-07",
      "has_results": false,
      "last_update_posted_date": "2020-02-12",
      "last_synced_at": "2026-10-24T15:58:17.938Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04060173"
    },
    {
      "nct_id": "NCT00462605",
      "title": "MS-275 and GM-CSF in Treating Patients With Myelodysplastic Syndrome and/or Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult Acute Megakaryoblastic Leukemia (M7)",
        "Adult Acute Minimally Differentiated Myeloid Leukemia (M0)",
        "Adult Acute Monoblastic Leukemia (M5a)",
        "Adult Acute Monocytic Leukemia (M5b)",
        "Adult Acute Myeloblastic Leukemia With Maturation (M2)",
        "Adult Acute Myeloblastic Leukemia Without Maturation (M1)",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Adult Acute Myelomonocytic Leukemia (M4)",
        "Adult Erythroleukemia (M6a)",
        "Adult Pure Erythroid Leukemia (M6b)",
        "Chronic Myelomonocytic Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Refractory Anemia",
        "Refractory Anemia With Excess Blasts",
        "Refractory Anemia With Ringed Sideroblasts",
        "Refractory Cytopenia With Multilineage Dysplasia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Untreated Adult Acute Lymphoblastic Leukemia",
        "Untreated Adult Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "entinostat",
          "type": "DRUG"
        },
        {
          "name": "sargramostim",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2007-04",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2017-07-18",
      "last_synced_at": "2026-10-24T15:58:17.938Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00462605"
    },
    {
      "nct_id": "NCT03715153",
      "title": "Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Autism Spectrum Disorder (ASD)"
      ],
      "interventions": [
        {
          "name": "BUMETANIDE (S95008) for week 0 - 26",
          "type": "DRUG"
        },
        {
          "name": "PLACEBO for week 0 - 26",
          "type": "DRUG"
        },
        {
          "name": "Open-Label BUMETANIDE (S95008) for weeks 26 - 52",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institut de Recherches Internationales Servier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "6 Years",
        "sex": "ALL",
        "summary": "2 Years to 6 Years"
      },
      "enrollment_count": 211,
      "start_date": "2018-10-04",
      "completion_date": "2021-10-26",
      "has_results": true,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-10-24T15:58:17.938Z",
      "location_count": 1,
      "location_summary": "Staten Island, New York",
      "locations": [
        {
          "city": "Staten Island",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03715153"
    },
    {
      "nct_id": "NCT03586661",
      "title": "Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Deleterious BRCA1 Gene Mutation",
        "Deleterious BRCA2 Gene Mutation",
        "Endometrial Adenocarcinoma",
        "High Grade Ovarian Serous Adenocarcinoma",
        "Platinum-Resistant Ovarian Carcinoma",
        "Primary Peritoneal High Grade Serous Adenocarcinoma",
        "Progressive Disease",
        "Recurrent Endometrial Carcinoma",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Copanlisib",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 31,
      "start_date": "2019-04-29",
      "completion_date": "2026-06-16",
      "has_results": false,
      "last_update_posted_date": "2026-07-23",
      "last_synced_at": "2026-10-24T15:58:17.938Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03586661"
    },
    {
      "nct_id": "NCT04402086",
      "title": "Rheumatology Patient Registry and Biorepository",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Rheumatic Diseases",
        "Adult Onset Still Disease",
        "Ankylosing Spondylitis",
        "Psoriatic Arthritis",
        "Reactive Arthritis",
        "Antiphospholipid Syndrome",
        "Systemic Lupus Erythematosus",
        "Behcet Disease",
        "Dermatomyositis",
        "Polymyositis",
        "Giant Cell Arteritis",
        "Lyme Disease",
        "Mixed Connective Tissue Disease",
        "Polymyalgia Rheumatica",
        "Rheumatoid Arthritis",
        "Sarcoidosis",
        "Systemic Sclerosis",
        "Scleroderma",
        "Sjogren's Syndrome",
        "Undifferentiated Connective Tissue Diseases"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 5000,
      "start_date": "2020-08-04",
      "completion_date": "2030-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-13",
      "last_synced_at": "2026-10-24T15:58:17.938Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402086"
    },
    {
      "nct_id": "NCT01273103",
      "title": "A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK2248761 Administered as an Oral Suspension to Healthy Adult Subjects",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Infection, Human Immunodeficiency Virus"
      ],
      "interventions": [
        {
          "name": "200mg [14C]- GSK2248761",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ViiV Healthcare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "30 Years to 55 Years · Male only"
      },
      "enrollment_count": 0,
      "start_date": "2011-01",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2014-05-19",
      "last_synced_at": "2026-10-24T15:58:17.938Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01273103"
    },
    {
      "nct_id": "NCT01351103",
      "title": "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pancreatic Cancer",
        "BRAF Mutant Colorectal Cancer",
        "Melanoma",
        "Triple Negative Breast Cancer",
        "Head and Neck Squamous Cell Cancer",
        "Cervical Squamous Cell Cancer",
        "Esophageal Squamous Cell Cancer",
        "Lung Squamous Cell Cancer"
      ],
      "interventions": [
        {
          "name": "LGK974",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2011-12-01",
      "completion_date": "2024-06-17",
      "has_results": false,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-10-24T15:58:17.938Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01351103"
    },
    {
      "nct_id": "NCT05316688",
      "title": "A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Oral Cavity Squamous Cell Carcinoma",
        "Stage I Lip and Oral Cavity Cancer AJCC v8",
        "Stage II Lip and Oral Cavity Cancer AJCC v8",
        "Stage III Lip and Oral Cavity Cancer AJCC v8",
        "Stage IVA Lip and Oral Cavity Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Near Infrared Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Tozuleristide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2024-04-17",
      "completion_date": "2025-09-26",
      "has_results": true,
      "last_update_posted_date": "2026-09-16",
      "last_synced_at": "2026-10-24T15:58:17.938Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05316688"
    },
    {
      "nct_id": "NCT04157751",
      "title": "A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 530,
      "start_date": "2020-05-18",
      "completion_date": "2021-06-02",
      "has_results": true,
      "last_update_posted_date": "2022-07-19",
      "last_synced_at": "2026-10-24T15:58:17.938Z",
      "location_count": 30,
      "location_summary": "Los Angeles, California • Orange, California • Torrance, California + 25 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Daytona Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04157751"
    }
  ]
}